Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Both Zepbound and Wegovy are FDA-approved GLP-1 receptor agonists, yet they target weight loss through different biological pathways and demonstrate distinct efficacy patterns in clinical trials. Understanding how these medications work—and what alternatives exist—helps you make an informed decision with your healthcare provider. PlexusDx specializes in personalized GLP-1 therapy, including compounded tirzepatide injection, which activates both GLP-1 and GIP receptors for dual-pathway weight management.
How Wegovy and Zepbound Work Differently
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone that regulates appetite and blood sugar. When semaglutide binds to GLP-1 receptors in the brain and digestive system, it slows gastric emptying, increases satiety signals, and reduces hunger hormones like ghrelin. This single-pathway mechanism makes semaglutide effective for weight loss and metabolic control.
Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 pathways simultaneously. By engaging two hormone systems, tirzepatide produces greater reductions in appetite and body weight compared to GLP-1-only agents in head-to-head trials. This dual mechanism also enhances insulin secretion in response to glucose, offering additional metabolic benefits beyond weight loss.
Clinical Efficacy: Weight Loss Results and Timelines
Semaglutide trials showed average weight reductions of 10–22% from baseline over 68 weeks, depending on dose level and patient population. In the STEP trials, participants using the highest maintenance dose achieved approximately 15% body weight loss on average. These results represent meaningful clinical improvement, particularly for individuals with obesity-related comorbidities like type 2 diabetes.
Tirzepatide demonstrated superior weight loss outcomes in the SURMOUNT trial series, with average reductions ranging from 15–22% at lower doses and up to 24% at the highest maintenance dose over comparable timeframes. Direct comparisons suggest tirzepatide produces approximately 3–5% greater weight loss than semaglutide at equivalent study durations. Both medications require consistent use over weeks to months to achieve peak effects, with most changes visible after 12–16 weeks of treatment.
Side Effects and Safety Profiles
Semaglutide commonly causes gastrointestinal side effects, including nausea, vomiting, diarrhea, and constipation, particularly during dose escalation phases. Most users experience mild-to-moderate symptoms that diminish within 2–4 weeks as the body adapts. Serious adverse events are rare but include pancreatitis, gallbladder issues, and thyroid-related complications in susceptible individuals.
Tirzepatide shares similar gastrointestinal side effect profiles with semaglutide but may produce slightly higher rates of nausea in early treatment phases due to dual-pathway activation. Long-term safety data remains less extensive than semaglutide, though clinical trials spanning up to 2 years show a comparable safety profile. Both medications carry black-box warnings related to thyroid tumors in animal studies, requiring screening before treatment initiation.
Cost and Access: Branded vs. Compounded Options
Zepbound and Wegovy are branded FDA-approved medications typically costing $900–$1,500 per month without insurance coverage. Insurance may cover these drugs if medical criteria are met, though prior authorization and documentation of obesity diagnosis are standard requirements. Out-of-pocket costs remain prohibitively high for many patients, especially across multi-month treatment timelines.
PlexusDx offers compounded tirzepatide injection starting at $249 per month, delivering the same dual GIP/GLP-1 mechanism as Zepbound from licensed 503A compounding pharmacies. PlexusDx also provides compounded semaglutide injection beginning at $149 per month, offering the Wegovy equivalent at substantially lower cost. HSA and FSA funds are eligible, and no insurance or membership fees are required—making personalized GLP-1 therapy accessible across all 50 states.
Personalization: Why Genetic Testing Matters
Not all patients respond equally to GLP-1 or GIP pathway activation due to natural genetic variation in appetite-regulating peptides and receptor function. Key genetic variants like GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 influence how efficiently your body activates these pathways and responds to therapy. Individuals with certain genetic profiles may achieve better outcomes with tirzepatide's dual approach, while others optimize results with semaglutide monotherapy.
PlexusDx offers the Precision Peptide Genetic Test as a $99 add-on after starting treatment, mapping 14 pathways and 49 peptides to generate 150+ personalized genetic insights. This peptide-pathway genetic analysis (distinct from standard pharmacogenomic testing) identifies which GLP-1 formulation, dose trajectory, and supporting compounds align with your unique biology. Precision-guided therapy reduces trial-and-error adjustments and accelerates time to therapeutic weight loss.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is tirzepatide more effective for weight loss than semaglutide?
Clinical trials show tirzepatide produces approximately 3–5% greater average weight loss than semaglutide over comparable periods, with some patients achieving up to 24% body weight reduction. However, individual response varies based on genetics, lifestyle, and metabolic factors. PlexusDx's Precision Peptide Genetic Test identifies whether dual GIP/GLP-1 activation or single GLP-1 therapy aligns best with your peptide pathways.
Can I switch from Wegovy to a compounded GLP-1 without problems?
Switching from branded semaglutide to compounded semaglutide is clinically straightforward since the active pharmaceutical ingredient is identical. PlexusDx compounded medications come from licensed 503A pharmacies meeting FDA sterility and potency standards. Always coordinate dosing transitions with your healthcare provider to ensure continuity and avoid unintended dose gaps.
How much can I save choosing PlexusDx compounded tirzepatide over Zepbound?
PlexusDx compounded tirzepatide injection starts at $249 per month compared to $900–$1,500 monthly for branded Zepbound, representing potential savings of $650–$1,250 monthly. Over a 12-month treatment period, PlexusDx pricing ranges from $2,988 annually versus $10,800–$18,000 for brand alternatives, making personalized GLP-1 therapy financially sustainable long-term.
Which medication causes fewer side effects?
Both semaglutide and tirzepatide produce comparable gastrointestinal side effects, with nausea and constipation being most common during dose escalation. Tirzepatide may trigger slightly higher early nausea rates due to dual-pathway activation, though most users adapt within 2–4 weeks. Genetic factors influence individual tolerance; PlexusDx's Precision Peptide Genetic Test can reveal predispositions affecting your side effect profile.
What does the Precision Peptide Genetic Test reveal about my GLP-1 response?
PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptides to identify genetic variants in GLP1R, GIPR, FTO, MC4R, and other appetite-regulating genes that influence medication response and weight loss outcomes. This $99 add-on test provides 150+ insights guiding whether semaglutide, tirzepatide, or combination therapy optimizes your results—enabling precision personalization beyond one-size-fits-all prescribing.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Weight Loss Medications During IVF: Can You Take Ozempic During IVF?
Optimizing Protein Intake While on Ozempic: A Guide to Fueling Your Journey